3728 related articles for article (PubMed ID: 16000336)
1. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
2. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
4. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
5. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
6. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
7. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
9. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
10. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
[TBL] [Abstract][Full Text] [Related]
11. Neuromelanin and Parkinson's disease.
Marsden CD
J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
[TBL] [Abstract][Full Text] [Related]
13. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
Halliday GM; Macdonald V; Henderson JM
Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
[TBL] [Abstract][Full Text] [Related]
14. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
15. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.
Zhou J; Broe M; Huang Y; Anderson JP; Gai WP; Milward EA; Porritt M; Howells D; Hughes AJ; Wang X; Halliday GM
Acta Neuropathol; 2011 Jun; 121(6):695-704. PubMed ID: 21400129
[TBL] [Abstract][Full Text] [Related]
16. [The mechanism of Lewy body formation in Parkinson's disease].
Wakabayashi K; Takahashi H
Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease.
Li JY; Englund E; Widner H; Rehncrona S; Björklund A; Lindvall O; Brundin P
Mov Disord; 2010 Jun; 25(8):1091-6. PubMed ID: 20198645
[TBL] [Abstract][Full Text] [Related]
18. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
Kovacs GG; Milenkovic IJ; Preusser M; Budka H
Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
[TBL] [Abstract][Full Text] [Related]
19. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
[TBL] [Abstract][Full Text] [Related]
20. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]